151 related articles for article (PubMed ID: 38601287)
1. Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial.
Ye G; Chen P; Liu X; He T; Pivot X; Pan R; Zhou D; Zhu L; Zhang K; Li W; Yang S; Lin J; Cai G; Huang H
Gland Surg; 2024 Mar; 13(3):374-382. PubMed ID: 38601287
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial.
Zhong X; He P; Chen J; Yan X; Wei B; Zhang Z; Bu H; Li J; Tian T; Lv Q; Wang X; Li H; Wang J; Huang J; Suo J; Liu X; Zheng H; Luo T
Gland Surg; 2022 Jan; 11(1):216-225. PubMed ID: 35242683
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of trastuzumab and albumin-bound paclitaxel with or without pyrotinib as neoadjuvant therapy for HER2-positive breast cancer: a prospective observational cohort study.
Wang Y; Xu Y; Liu X; Li C; Wang J; Zhang X; Shao B; Zhang J
Gland Surg; 2024 May; 13(5):654-662. PubMed ID: 38845840
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of using pyrotinib combined with capecitabine as neoadjuvant therapy in elderly patients with HER2-positive breast cancer: a single-arm prospective clinical trial.
Wang W; Zhang J; Chang JY; Yao DS; Hu F; Liang YP; Shen Y; Liu YQ; Qi HH; Tong JB; Cai HF
Gland Surg; 2023 Feb; 12(2):208-214. PubMed ID: 36915823
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant pyrotinib plus nab-paclitaxel, doxorubicin, and cyclophosphamide for HER2-positive locally advanced breast cancer: a retrospective case-series study.
Yao DS; Wang W; Chang JY; Zhang Y; Zhang HW; Xu JX; Cai HF
Gland Surg; 2021 Dec; 10(12):3362-3368. PubMed ID: 35070896
[TBL] [Abstract][Full Text] [Related]
6. Clinical observation of neoadjuvant chemotherapy with pyrotinib plus trastuzumab in HER2-positive breast cancer: a cohort study.
Li Q; Wang Y; Zhu M; Gu Y; Tang Y
Gland Surg; 2021 Dec; 10(12):3389-3402. PubMed ID: 35070899
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study.
Li F; Liang Y; Luo M; Shen J; Zhou T; Liang Y; Tang X; Yuan H; Zeng J
Front Oncol; 2023; 13():1041111. PubMed ID: 36793595
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I-III HER2-Positive Breast Cancer: A Phase II Clinical Trial.
Xuhong J; Qi X; Tang P; Fan L; Chen L; Zhang F; Tan X; Yan W; Zhong L; He C; Liang Y; Ren L; Wang M; Zhang Y; Jiang J
Oncologist; 2020 Dec; 25(12):e1909-e1920. PubMed ID: 33000490
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study.
Liu L; Zhu M; Wang Y; Li M; Gu Y
World J Surg Oncol; 2023 Dec; 21(1):389. PubMed ID: 38114991
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.
Wu J; Jiang Z; Liu Z; Yang B; Yang H; Tang J; Wang K; Liu Y; Wang H; Fu P; Zhang S; Liu Q; Wang S; Huang J; Wang C; Wang S; Wang Y; Zhen L; Zhu X; Wu F; Lin X; Zou J
BMC Med; 2022 Dec; 20(1):498. PubMed ID: 36575513
[TBL] [Abstract][Full Text] [Related]
11. Pyrotinib-Containing Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis.
Mao X; Lv P; Gong Y; Wu X; Tang P; Wang S; Zhang D; You W; Wang O; Zhou J; Li J; Jin F
Front Oncol; 2022; 12():855512. PubMed ID: 35463365
[TBL] [Abstract][Full Text] [Related]
12. Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study.
Wang H; Li Y; Qi Y; Zhao E; Kong X; Yang C; Yang Q; Zhang C; Liu Y; Song Z
Front Oncol; 2022; 12():909426. PubMed ID: 35875123
[TBL] [Abstract][Full Text] [Related]
13. Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A phase II single-arm study.
Yang Y; Jin L; Li Y; Rao N; Gong C; Li S; Wu J; Zhao J; Ding L; Gan F; Zhang J; Feng R; Liu Z; Liu Q
Chin J Cancer Res; 2024 Feb; 36(1):55-65. PubMed ID: 38455369
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive Breast Cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Ding Y; Mo W; Xie X; Wang O; He X; Zhao S; Gu X; Liang C; Qin C; Ding K; Yang H; Ding X
Oncol Res Treat; 2023; 46(7-8):303-311. PubMed ID: 37302393
[TBL] [Abstract][Full Text] [Related]
15. [Role of clustered HER2/neu amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer].
Kolyadina IV; Zavalishina LE; Ganshina IP; Andreeva YY; Frank GA; Gordeeva OO; Zhukova LG; Meshcheryakov AA; Savelov NA; Tuzova EA; Morozov DA; Poddubnaya IV
Arkh Patol; 2019; 81(6):56-62. PubMed ID: 31851193
[TBL] [Abstract][Full Text] [Related]
16. A multicenter single-arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer.
Shi Q; Qi X; Tang P; Fan L; Chen L; Wang S; Liang Y; Hu Y; Wang M; Ren L; Zhang G; Tan X; Yuan L; Du J; Wu X; Wang M; Che H; Lv P; Chen D; Hu J; Li Q; Zhang Y; Yang K; Zhong Y; Chen C; Zhou Z; Qian L; Zhang J; Ma M; Sun Y; Zhang Y; Jiang J
MedComm (2020); 2023 Dec; 4(6):e435. PubMed ID: 38077249
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial.
Man X; Huang J; Sun S; Zhou D; Zhang B; Fang S; Zheng F; Li C; Wang X; Huang W; Wang L; He Q; Fu H; Zhang Y; Liu C; Dong L; Zhao X; Xu L; Sun X; Fan B; Song L; Zhou Z; Yu J; Li H
Clin Transl Med; 2024 May; 14(5):e1687. PubMed ID: 38738791
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).
Wang C; Zhou Y; Lin Y; Mao F; Guan J; Zhang X; Shen S; Wang X; Zhang Y; Pan B; Zhong Y; Peng L; Cao X; Yao R; Zhou X; Xu C; Xu Y; Sun Q
BMC Cancer; 2022 Mar; 22(1):269. PubMed ID: 35287613
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study.
Yin W; Wang Y; Wu Z; Ye Y; Zhou L; Xu S; Lin Y; Du Y; Yan T; Yang F; Zhang J; Liu Q; Lu J
Clin Cancer Res; 2022 Sep; 28(17):3677-3685. PubMed ID: 35713517
[TBL] [Abstract][Full Text] [Related]
20. Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial.
Liu Z; Wang C; Chen X; Zhu J; Sun X; Xia Q; Lu Z; Qiao J; Zhou Y; Wang H; Wang Y; Yan M
Eur J Cancer; 2022 Apr; 165():157-168. PubMed ID: 35235873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
